GeoVax Labs, Inc. (GOVX) News

GeoVax Labs, Inc. (GOVX): $0.88

-0.01 (-1.17%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GOVX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 401

in industry

Filter GOVX News Items

GOVX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GOVX News Highlights

  • GOVX's 30 day story count now stands at 4.
  • Over the past 14 days, the trend for GOVX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • BIO, MOD and VAC are the most mentioned tickers in articles about GOVX.

Latest GOVX News From Around the Web

Below are the latest news stories about GEOVAX LABS INC that investors may wish to consider to help them evaluate GOVX as an investment opportunity.

GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines

Focused on Providing Rapid Response to Combat Emerging Infectious Threats ATLANTA, GA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced significant progress in developing a high-yield, high-capacity, continuous avian cell line system for manufacturing its MVA (modified vaccinia Ankara)-based vaccines and immunotherapies. Currently, MVA vac

Yahoo | February 8, 2023

GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers

Phase 1/2 Trial Now Active at Stanford, Emory, and Thomas Jefferson Universities ATLANTA, GA, Feb. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today its clinical trial of Gedeptin® for patients with recurrent head and neck cancers is now actively enrolling patients at three major research centers -- Stanford University, Emory University and Thom

Yahoo | February 7, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to start the final day of trading this week with a look at the biggest pre-market stock movers for Friday morning!

William White on InvestorPlace | January 27, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off the day with an overview of the biggest pre-market stock movers that traders need to watch on Thursday!

William White on InvestorPlace | January 26, 2023

GeoVax to Present at the 2023 BIO CEO & Investor Conference

ATLANTA, GA, Jan. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 2023 BIO CEO & Investor Conference taking place in-person in New York City at the New York Marriott Marquis and virtually on February 6-9, 2023. BIO CEO & Investor Conference Date: Tuesday, February 7, 2023 Time: 3:45 PM

Yahoo | January 26, 2023

Why Is GeoVax (NASDAQ:GOVX) Stock Up 80% Today?

A notice from the U.S.

Bret Kenwell on InvestorPlace | January 25, 2023

GeoVax Receives Notice of Allowance for Zika Vaccine Patent

Preclinical Evaluation Demonstrated 100% Protection Against a Lethal Dose of Zika Virus ATLANTA, GA, Jan. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that the U.S. Patent and Trademark Office issued a Notice of Allowance for Patent Application No. 17/000,768 titled, “Method for Generating a ZIKV Immune Response Utilizing a Recombinant Mod

Yahoo | January 25, 2023

GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023

ATLANTA, GA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that it will present at the Biotech Showcase coinciding with the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, January 9-12, 2023. Presentation Details: Presenter: David Dodd, Chairman & CEO Date/Time: January 9, 2023, 5:00 pm PST Location: Hilton Union Square,

Yahoo | January 4, 2023

Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax

First Woman President and CEO of MSM and Internationally Recognized Health Equity Advocate Joins in GeoVax Special Advisory Role ATLANTA, GA, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the appointment of Valerie Montgomery Rice, MD, FACOG, Morehouse School of Medicine President and CEO, as Special Advisor to the Chairman/CEO and Boa

Yahoo | December 20, 2022

GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors

Dr. Morgan Brings Extensive COVID-19, Medical and Healthcare Management Expertise ATLANTA, GA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that it has appointed Jayne Morgan, M.D., to its Board of Directors. Dr. Morgan is an accomplished and forward-thinking healthcare management executive and research leader with extensive expertise

Yahoo | December 7, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.8086 seconds.